Celldex (CLDX) Announces up to $175M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh
July 14, 2021 5:04 AM EDTCelldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering. LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead... More
Celldex Therapeutics (CLDX) PT Raised to $61 at Cantor Fitzgerald
July 12, 2021 1:22 PM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $61.00 (from $35.00) while maintaining a Overweight rating.
... MoreCelldex Therapeutics (CLDX) Gains on CDX-0159 Update, Which Has Drug 'In the Driver's Seat'
July 12, 2021 10:18 AM EDTCelldex Therapeutics (NASDAQ: CLDX) shares are ramping 30% in early trading Monday following updated data from the companys ongoing Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.
The update highlights several key metrics:
All 19/19 (100%) patients experienced a clinical response as assessed by provocation threshold testing; 18/19 (95%) experienced a complete response and 1/19 (5%) experienced a partial response.Rapid onset of responses after... MorePre-Open Stock Movers 07/12: (STFC) (CLDX) (SPI) Higher; (TBLT) (DIDI) (RKT) Lower (more...)
July 12, 2021 9:28 AM EDTPre-Open Stock Movers
State Auto Financial Corporation (NASDAQ: STFC) 189% HIGHER; Liberty Mutual Holding Company Inc., State Automobile Mutual Insurance Company, and State Auto Financial Corporation (NASDAQ: STFC) announced today that they have signed a definitive agreement pursuant to which Liberty Mutual would acquire State Auto Group, a super-regional insurance holding company headquartered in Columbus, Ohio. Under the terms of the agreement, State Auto mutual members will become mutual members of Liberty Mutual and Liberty Mutual will acquire all of the publicly held... More
Celldex Therapeutics (CLDX) PT Raised to $50 at H.C. Wainwright
July 12, 2021 6:21 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $50.00 (from $36.00) while maintaining a Buy rating following updated Phase 1b data from the ongoing Phase 1b study of CDX-0159.
The analyst commented, "Celldex reported updated Phase 1b data from the ongoing Phase 1b study of... More
